Completed PHASE3 INTERVENTIONAL 2-arm NCT00966914

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Sponsor: BioNumerik Pharmaceuticals, Inc.

Conditions Non-small Cell Lung Cancer

Interventions Placebo in combination with cisplatin and docetaxel or paclitaxel Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel

Updated 11 times since 2017 Last updated: Jul 11, 2022 Started: Apr 30, 2010 Primary completion: Apr 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00966914, this PHASE3 trial focuses on Non-small Cell Lung Cancer and remains completed. Sponsored by BioNumerik Pharmaceuticals, Inc., it has been updated 11 times since 2010, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2022 [monthly]

Completed PHASE3

▶ Show 6 earlier versions

Apr 2020 — Jan 2021 [monthly]

Completed PHASE3
Aug 2019 — Apr 2020 [monthly]

Completed PHASE3
Nov 2018 — Aug 2019 [monthly]

Completed PHASE3
Jun 2018 — Nov 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioNumerik Pharmaceuticals, Inc.
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.

Data source: BioNumerik Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkangelsk, Russia , Birmingham, United States , Brasov, Romania , Bucharest, Romania , Chelyabinsk, Russia , Chernihiv, Ukraine , Cluj-Napoca, Romania , Columbia, United States , Craiova, Romania , Dnipropetrovsk, Ukraine and 30 more locations